Navigation Links
New Ovarian Cancer Biomarker Research Act Introduced
Date:10/2/2007

Funding, Research and National Trials Crucial in the Fight Against Women's

Cancers

WASHINGTON, Oct. 2 /PRNewswire-USNewswire/ -- The Ovarian Cancer Biomarker Research Act of 2007 was introduced in the U.S. House of Representatives on Thursday, Sept. 27 and the Society of Gynecologic Oncologists (SGO), the leader of four organizations integral in drafting this legislation, is issuing a "call to action" for ovarian cancer survivors, their families, and their physicians.

Introduced by Congressmen Howard L. Berman (D-CA) and Ralph M. Hall (D-TX), the Ovarian Cancer Biomarker Research Act would authorize the National Cancer Institute (NCI) to make grants to public or non-profit entities for the establishment of research centers focused on ovarian cancer biomarkers. Biomarkers are the biochemical features within the body that can be used to determine the presence and population of cancerous cells, predict response to therapy, and determine ultimate prognosis. Additionally, the Ovarian Cancer Biomarker Research Act will also establish a national clinical trial to determine the clinical utility of ovarian cancer biomarkers in diagnosing or preventing ovarian cancer in at-risk women.

SGO, which is the professional organization for gynecologic oncologists, specialists in women's cancers, collaborated with the American College of Obstetricians and Gynecologists (ACOG), the Ovarian Cancer National Alliance, and the American College of Surgeons (ACS) to spearhead the development of the Ovarian Cancer Biomarker Research Act in order to secure dedicated support for ovarian cancer biomarkers research. Currently, a widely accepted or effective screening test for ovarian cancer is not available -- making the disease difficult to diagnose.

"Early diagnosis is critical," said Beth Karlan, MD, Director of the Cedars-Sinai Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute and an expert in the field of gynecologic oncology, ovarian cancer surgery, and inherited cancer susceptibility. "Women have just recently been made aware of the symptoms of ovarian cancer, but many of these symptoms can be easily confused with those of other diseases. Development of an effective biomarker screening test is imperative to saving the lives of women with ovarian cancer."

"What we need now is wide-spread action," adds Carol Brown, MD, a gynecologic oncologist at Memorial Sloan-Kettering Cancer Center and SGO's Government Relations Committee Chair. "The bill has been introduced, but it hasn't been passed yet. We are so appreciative that the Ovarian Cancer Biomarker Research Act has come this far, and we are grateful for the help and support we have received from Congressmen Berman and Hall, but we need to make sure that that this bill is passed. We need every woman, every family, every physician to contact their Congressmen and express their support for the Ovarian Cancer Biomarkers Research Act. It is quite literally -- and quite unfortunately -- a matter of life and death."

Adds Lindy Graham, an ovarian cancer survivor and advocate, "We absolutely need to pass this bill so our daughters, sisters, mothers, friends and neighborhood of women will finally be able to obtain early ovarian cancer detection that will ultimately save lives. No more sneak attacks from this disease!"

About SGO

The Society of Gynecologic Oncologists (SGO) is a national medical specialty society for physicians trained in the comprehensive management of women's cancers. The Society's membership is primarily comprised of gynecologic oncologists -- obstetrician/gynecologists who undertake an additional 3-4 years of intensive training in the specific study of gynecologic cancers. SGO members provide medical and surgical care to women with ovarian cancer, cervical cancer, endometrial cancer, vulvar cancer, and vaginal cancer. They are trained to in chemotherapy and radiation therapy administration, supportive care, and surgery in order to provide comprehensive care to their patients. More information on gynecologic oncology, the SGO, and its members can be found at http://www.sgo.org.

Contact: Jessica Schackmuth

Cell: (312) 235-4060


'/>"/>
SOURCE Society of Gynecologic Oncologists
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Vitamin D Reduces Chances of Colon, Breast And Ovarian Cancers by 50%
3. Progestin protects against ovarian cancer
4. Inherited gene important in ovarian cancer
5. Blood test may identify ovarian cancer
6. Exercise lowers Risk of Ovarian Cancer
7. Screening device for ovarian cancer
8. Ethnic discrepancy in ovarian cancer
9. Associated scan for detecting ovarian cancer spread
10. Gene Mutation Causes Ovarian Failure
11. Ovarian Cancer Screening Questioned
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, ... and around the greater Phoenix metropolitan region, is announcing a charity event to ... of the Homeless Youth Connection is to promote community awareness of the ongoing ...
(Date:12/8/2016)... ... , ... The Compretta Insurance Agency, a family owned insurance and financial consultation ... County area, is announcing the launch of a charity effort aimed at raising funds ... Pantry has worked for more than 30 years to meet the food needs of ...
(Date:12/8/2016)... ... 08, 2016 , ... Bill Mull Agencies, a Wichita-based firm ... around central Kansas, is joining the Youth Horizons organization for a charity event ... in Wichita, Youth Horizons works to empower area children from unstable, troubled, or ...
(Date:12/7/2016)... ... 07, 2016 , ... Students attending Envision’s summer 2017 ... get hands-on experience in an emergency medical simulation, When Care is Hours Away. ... real-life medical skills that are critical success in a future career and beyond. ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc ... Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... Dec. 8, 2016 Bodycad announced it ... improving the accuracy, reproducibility and speed for 3D ... and small bone orthopaedic applications. These patents are ... personalized orthopaedic restorations based on each patient,s distinct ... the company harnesses the world,s first suite of ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology: